Acute lymphoblastic leukaemia: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 122
• CD22 33
• ABL1 10
• KMT2A 8
• CD20 8
• TP53 0
• AKT 0
• BCL-2 3
• PI3K 0
• CD123 5
• JAK 2
• CD38 4
• PD-1 3
• RUNX1 0
• mTOR 0
• NPM1 4
• BCMA 4
• NOTCH1 0
• CXCR4 1
• PTEN 0
• CTNNB1 0
• EGFR 0
• HDAC 0
• IDH 0
• MYC 0
• RAS 0
• STAT3 0
• AMPK 0
• CD30 0
• CD40 0
• CD47 0
• ERK 0
• FGFR 0
• MAPK 0
• MDM2 0
• PD-L1 0
• CD33 1
• FLT3 0
• IL-1 0
• IL-17 0
• IL-6 0
• KRAS 0
• MEK 0
• PPAR 0
• RANKL 0
• RB1 0
• TYK2 0
• ALK 0
• AXL 0
• BRCA1 0
• BRD4 0
• BTK 0
• CDK4/6 0
• CDKN2A 0
• CTLA-4 0
• EZH2 0
• FAK 0
• FTO 0
• GPRC5D 1
• GPX4 0

19 of 19+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Italy· EU contribution €150,000· until Mar 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  TOWARDS THE ELIMINATION OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN THROUGH IDENTIFICATION OF THEIR ENVIRONMENTAL CAUSES (ELI-ALL)

  Centre International de Recherche Sur Le Cancer· Lyon 7eme, France· EU contribution €6,502,240· until Aug 2031· 12 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  THERAPEUTIC ANTIBODIES NEUTRALIZING ALL THE ORTHOPOXVIRUS INFECTIOUS FOR HUMANS, INCLUDING SMALLPOX (THANATOS)

  Commissariat A L Energie Atomique Et Aux Energies Alternatives· Paris, France· EU contribution €13,557,641· until Aug 2031· 6 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Role of RAS mutant subclones in the development of High Hyperdiploid B-ALL (RasWayToALL)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution €200,400· until Jun 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Science, Innovation, Health, Earth, And Life Technologies for ALL (SCIENCE4ALL)

  Istinye University· Istanbul, Türkiye· EU contribution €350,000· until Jun 2028

5 of 13 running projects, newest first. Listed amounts together: €62.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

  NCT03576547· M.D. Anderson Cancer Center· Updated 8 May 2025

  “The study was terminated early due to slow accrual and low level of interest both by the sponsor and by the department”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

  NCT04530565· National Cancer Institute (NCI)· Source

• Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

  NCT07387926· Novartis Pharmaceuticals· Source

• Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL

  2025-522019-40-00· Novartis Pharma AG· Source

• Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL

  NCT07301424· University of Alberta· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 4
• CRISPR-Cas Systems 5
• Gene Expression Profiling 27
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 7
• Metabolomics 4
• Flow Cytometry 40
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 50
• Magnetic Resonance Imaging 14
• Machine Learning 11
• Deep Learning 8
• Cohort Studies 26
• Genome-Wide Association Study 8

• Recharacterization of EmAGA, a Potential Candidate for Novel ALL Therapeutics.

  Biomolecules, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.